

Martin Aringer

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9322508/martin-aringer-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

147
papers

12,779
citations

46
h-index

112
g-index

242
ext. papers

16,619
ext. citations

6.1
avg, IF

6.06
L-index

#	Paper	IF	Citations
147	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 960-977	27.4	1649
146	Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. <i>Cell</i> , 1999 , 97, 133-44	56.2	1008
145	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 685-699	27.4	851
144	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 3-15	2.4	814
143	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1771-82	2.4	692
142	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 736-745	2.4	628
141	Trial of Tocilizumab in Giant-Cell Arteritis. <i>New England Journal of Medicine</i> , 2017 , 377, 317-328	59.2	578
140	SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. <i>Nature Genetics</i> , 2008 , 40, 437-42	36.3	563
139	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1400-1412	9.5	488
138	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 958-67	2.4	388
137	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1151-1159	2.4	344
136	The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. <i>Blood</i> , 2000 , 95, 3223-3231	2.2	306
135	Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. <i>Arthritis and Rheumatism</i> , 2004 , 50, 3161-9		265
134	Ultrasound therapy for calcific tendinitis of the shoulder. <i>New England Journal of Medicine</i> , 1999 , 340, 1533-8	59.2	225
133	Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. <i>Journal of Immunology</i> , 2000 , 164, 1768-74	5.3	196
132	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 554-561	2.4	175
131	2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 713-723	2.4	173

130	Role of interleukin-6 in stress, sleep, and fatigue. <i>Annals of the New York Academy of Sciences</i> , 2012 , 1261, 88-96	6.5	167
129	Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. <i>Rheumatology</i> , 2009 , 48, 1451-4	3.9	144
128	Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation. <i>Journal of Immunology</i> , 2000 , 164, 4659-64	5.3	144
127	Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. <i>Journal of Clinical Investigation</i> , 2015 , 125, 413-24	15.9	139
126	Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). <i>Arthritis Research and Therapy</i> , 2011 , 13, R75	5.7	136
125	The role of tumor necrosis factor-alpha in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2008 , 10, 202	5.7	109
124	Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 137, 130-136	11.5	108
123	"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. <i>Seminars in Arthritis and Rheumatism</i> , 2012 , 41, 589-98	5.3	88
122	High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes, of patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1994 , 37, 1423-30		87
121	Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data. <i>Arthritis Care and Research</i> , 2018 , 70, 428-438	4.7	86
120	Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007 , 56, 274-9		85
119	Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1463-71		80
118	The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 966-9	2.4	80
117	Therapeutic blockade of TNF in patients with SLE-promising or crazy?. <i>Autoimmunity Reviews</i> , 2012 , 11, 321-5	13.6	76
116	Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. <i>Arthritis Care and Research</i> , 2018 , 70, 571-581	4.7	74
115	New treatments for SLE: cell-depleting and anti-cytokine therapies. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005 , 19, 859-78	5.3	71
114	SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. <i>Arthritis Research</i> , 2003 , 5, 172-7		67
113	Impact of sonography in gouty arthritis: comparison with conventional radiography, clinical examination, and laboratory findings. <i>European Journal of Radiology</i> , 2007 , 62, 437-43	4.7	66

112	Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. <i>Journal of Rheumatology</i> , 2002 , 29, 1430-6	4.1	63
111	Brief Report: How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. <i>Arthritis and Rheumatology</i> , 2019 , 71, 91-98	9.5	60
110	Severe infections in plasmapheresis-treated systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1998 , 41, 414-20		58
109	Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health status. <i>Arthritis and Rheumatism</i> , 2007 , 57, 1287-95		57
108	Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. <i>Rheumatology</i> , 2014 , 53, 1630-8	3.9	56
107	Does mixed connective tissue disease exist? Yes. <i>Rheumatic Disease Clinics of North America</i> , 2005 , 31, 411-20, v	2.4	55
106	Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature. <i>Journal of Clinical Microbiology</i> , 2005 , 43, 2537-41	9.7	54
105	Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. <i>Rheumatology</i> , 2013 , 52, 1070-6	3.9	52
104	Gout--current diagnosis and treatment. <i>Deutsches A&#x0308;rztblatt International</i> , 2009 , 106, 549-55		51
103	Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1194-9	2.4	47
102	Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. <i>Expert Opinion on Drug Safety</i> , 2008 , 7, 411-9	4.1	46
101	Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1329-1338	9.5	42
100	Inflammatory markers in systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020 , 110, 102374	15.5	40
99	Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: A patient Delphi exercise. <i>Arthritis and Rheumatism</i> , 2009 , 61, 21-8		38
98	Multicenter Delphi Exercise to Identify Important Key Items for Classifying Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018 , 70, 1488-1494	4.7	36
97	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 634-640	2.4	35
96	Indication Criteria for Total Knee Arthroplasty in Patients with Osteoarthritis - A Multi-perspective Consensus Study. <i>Zeitschrift Fur Orthopadie Und Unfallchirurgie</i> , 2017 , 155, 539-548	1.1	29
95	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019 , 46, 721-726	4.1	29

94	Interferon signals and monocytic sensitization of the interferon-β signaling pathway in the peripheral blood of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 400-8		28
93	Innate immune processes in lupus erythematosus. <i>Clinical Immunology</i> , 2013 , 147, 216-22	9	27
92	EULAR/ACR classification criteria for SLE. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, S14-S17	5.3	27
91	Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young Adulthood. <i>Arthritis Care and Research</i> , 2019 , 71, 471-481	4.7	26
90	Characterization and analysis of the proximal Janus kinase 3 promoter. <i>Journal of Immunology</i> , 2003 , 170, 6057-64	5.3	26
89	Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). <i>Journal of Rheumatology</i> , 2012 , 39, 2153-6	4.1	25
88	Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. <i>Rheumatology International</i> , 2018 , 38, 569-577	3.6	25
87	The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	24
86	EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1178-82	2.4	24
85	Classifying and diagnosing systemic lupus erythematosus in the 21st century. <i>Rheumatology</i> , 2020 , 59, v4-v11	3.9	23
84	Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1986-90	2.4	22
83	Mixed connective tissue disease: what is behind the curtain?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007 , 21, 1037-49	5.3	22
82	Immunoadsorption (IAS) as a rescue therapy in SLE: considerations on safety and efficacy. <i>Wiener Klinische Wochenschrift</i> , 2004 , 116, 716-24	2.3	22
81	Response to: European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist's point of view by Infantino. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e189	2.4	21
80	New Criteria for Lupus. <i>Current Rheumatology Reports</i> , 2020 , 22, 18	4.9	18
79	Validation of Standardized Questionnaires Evaluating Symptoms of Depression in Rheumatoid Arthritis Patients: Approaches to Screening for a Frequent Yet Underrated Challenge. <i>Arthritis Care and Research</i> , 2017 , 69, 58-66	4.7	18
78	A 3-day delay in synovial fluid crystal identification did not hinder the reliable detection of monosodium urate and calcium pyrophosphate crystals. <i>Journal of Clinical Rheumatology</i> , 2013 , 19, 241-5 ^{1.1}		16
77	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1333-1339	2.4	16

76	Gastrointestinal SLE involvement in SLE classification. Response to: R 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus R by Aringer R by Cui. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	16
75	Associations Between Classification Criteria Items in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020 , 72, 1820-1826	4.7	16
74	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. <i>Arthritis Research and Therapy</i> , 2018 , 20, 174	5.7	15
73	A bridge between interferon-alpha and tumor necrosis factor in lupus. <i>Journal of Rheumatology</i> , 2008 , 35, 1473-6	4.1	15
72	New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis - Implications from the prospective multicenter VADERA II study. <i>PLoS ONE</i> , 2019 , 14, e0217412	3.7	14
71	Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. <i>Lancet Rheumatology, The</i> , 2021 , 3, e328-e336	14.2	14
70	International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis. <i>Arthritis Research and Therapy</i> , 2012 , 14, R2	5.7	13
69	Immunoadsorption in Autoimmune Diseases Affecting the Kidney. <i>Seminars in Nephrology</i> , 2017 , 37, 478-487	4.8	12
68	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. <i>Microvascular Research</i> , 2015 , 102, 19-24	3.7	11
67	Immunoadsorption Followed by Rituximab as a Definitive Treatment for Insulin Autoimmune Syndrome (Hirata Syndrome): A Case Report. <i>Diabetes Care</i> , 2018 , 41, e23-e24	14.6	10
66	Role of tumor necrosis factor alpha and potential benefit of tumor necrosis factor blockade treatment in systemic lupus erythematosus: comment on the editorial by Pisetsky. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1721-2		10
65	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	10
64	Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal?. <i>Clinical and Experimental Rheumatology</i> , 2013 , 31, S71-4	2.2	10
63	Engineering anticancer T cells for extended functional longevity. <i>Annals of the New York Academy of Sciences</i> , 2004 , 1019, 178-85	6.5	9
62	Safety of off-label biologics in systemic lupus erythematosus. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 243-51	4.1	8
61	The Janus faces of allopurinol-allopurinol hypersensitivity syndrome. <i>American Journal of Medicine</i> , 2008 , 121, e3-4	2.4	8
60	New classification criteria for systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 590-596	5.3	8
59	Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2021 , 73, 671-676	9.5	8

58	Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1226-36		7
57	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	7
56	Relevant concepts of functioning for patients with systemic lupus erythematosus identified in a Delphi exercise of experts and a literature review. <i>Arthritis Care and Research</i> , 2014 , 66, 1895-904	4.7	6
55	Tophaceous gout and renal insufficiency: a new solution for an old therapeutic dilemma. <i>Case Reports in Medicine</i> , 2011 , 2011, 397646	0.7	6
54	Understanding deficient elimination of uric acid. <i>Lancet, The</i> , 2008 , 372, 1929-30	4.0	6
53	Periodic fever syndromes--a clinical overview. <i>Vienna Clinical Weekly</i> , 2004 , 31, 8-12		6
52	Mixed lymphohematopoietic chimerism and response in Wegener's granulomatosis. <i>New England Journal of Medicine</i> , 2010 , 362, 2431-2	59.2	5
51	Chemosensory function is decreased in rheumatoid arthritis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020 , 277, 1675-1680	3.5	4
50	Engulfed cell remnants, and not cells undergoing apoptosis, constitute the LE-cell phenomenon. <i>Autoimmunity</i> , 2007 , 40, 315-21	3	4
49	Treat to Target in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2019 , 45, 537-548	2.4	4
48	Association of Dendritic Cell Signatures With Autoimmune Inflammation Revealed by Single-Cell Profiling. <i>Arthritis and Rheumatology</i> , 2019 , 71, 817-828	9.5	4
47	Systemic sclerosis phase III clinical trials: Hope on the horizon?. <i>Journal of Scleroderma and Related Disorders</i> , 2018 , 3, 193-200	2.3	4
46	Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort. <i>Lupus</i> , 2021 , 30, 431-438	2.6	4
45	Relevant incidence of cervical arthritis in patients with erosive seropositive rheumatoid arthritis even today. <i>Clinical and Experimental Rheumatology</i> , 2013 , 31, 213-8	2.2	4
44	Parvovirus infection in early arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 207-13	2.2	4
43	Difference between SLE classification and diagnosis and importance of attribution. Response to: Do the 2019 EULAR/ACR SLE classification criteria close the door on certain groups of SLE patients? By Chi. <i>Annals of the Rheumatic Diseases</i> , 2019 ,	2.4	3
42	TNF-alpha blockade with infliximab in a patient with lupus erythematosus profundus. <i>Acta Dermato-Venereologica</i> , 2012 , 92, 401-3	2.2	3
41	New lupus criteria: a critical view. <i>Current Opinion in Rheumatology</i> , 2021 , 33, 205-210	5.3	3

40	FRI0193 2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS 2019 ,		3
39	Systemic lupus erythematosus does not prevent antibody responses to SARS-CoV-2. <i>Lancet Rheumatology, The</i> , 2021 , 3, e538-e540	14.2	3
38	Serum of patients with antiphospholipid syndrome induces adhesion molecules in endothelial cells. <i>Atherosclerosis Supplements</i> , 2017 , 30, 141-148	1.7	2
37	SLE classification criteria items are not dependent on current activity but may accumulate over time. Response to: Do 2019 European League against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus also indicate the disease activity? By Teng. <i>Annals of the Rheumatic Diseases</i> , 2020	2.4	2
36	High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockers. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 561-2	2.4	2
35	Response to: Correspondence on Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities By Ronnelid. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	2
34	New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. <i>Rheumatology</i> , 2021 ,	3.9	2
33	Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1175-1182	2.4	2
32	Response to: New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion By Sacre. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e191	2.4	2
31	Swimming against the stream: the fishbowl discussion method as an interactive tool for medical conferences: experiences from the 11th European Lupus Meeting. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 713-714	2.4	2
30	Severe infections in plasmapheresis-treated systemic lupus erythematosus 1998 , 41, 414		2
29	A glimpse into the future of systemic lupus erythematosus.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022 , 14, 1759720X221086719	3.8	2
28	Tocilizumab in the treatment of giant cell arteritis. <i>Immunotherapy</i> , 2018 , 10, 465-472	3.8	1
27	Effector Mechanisms in Autoimmunity 2014 , 311-318		1
26	Reply. <i>Arthritis and Rheumatology</i> , 2020 , 72, 695-696	9.5	1
25	European League Against Rheumatism (EULAR) recommendations and EULAR/American College of Rheumatology criteria-documenting progress in lupus. <i>Rheumatology</i> , 2021 , 60, 2976-2978	3.9	1
24	Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study). <i>Rheumatology</i> , 2021 , 60, 5318-5328	3.9	1
23	Systemic Lupus Erythematosus Classification and Diagnosis. <i>Rheumatic Disease Clinics of North America</i> , 2021 , 47, 501-511	2.4	1

22	Reply. <i>Arthritis Care and Research</i> , 2019 , 71, 696-697	4.7	1
21	Janus kinase inhibitors clear to land. <i>Rheumatology</i> , 2018 , 57, 1131-1132	3.9	1
20	Glucocorticoid dosing and relapses in giant cell arteritis-a single center cohort study. <i>Rheumatology</i> , 2021 ,	3.9	1
19	Diagnosis and Classification of Systemic Lupus Erythematosus 2021 , 51-66		1
18	ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 319-328	2.2	1
17	Frauen und Gicht Eine diagnostische Herausforderung. <i>Aktuelle Rheumatologie</i> , 2021 , 46, 62-69	0.1	0
16	Response to: Correspondence on "European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance" by Aringer. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	0
15	Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021 , 35, 101672	5.3	0
14	Improvement of cutaneous inflammation and panniculitis in dermatomyositis patients by the JAK-inhibitor baricitinib.. <i>British Journal of Dermatology</i> , 2022 ,	4	0
13	Neue Klassifikationskriterien des SLE: was helfen sie für die klinische Diagnose des SLE?. <i>Aktuelle Rheumatologie</i> , 2020 , 45, 299-306	0.1	
12	Reply. <i>Arthritis and Rheumatology</i> , 2020 , 72, 860-861	9.5	
11	Reply. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1404	9.5	
10	Essential and Optional Drugs for Rheumatic Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2018 , 77-96	0.3	
9	Clinical applications of IFN-Blockade in systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2009 , 4, 617-619	1.5	
8	Targeted Therapies Many Ways to (the Peace of) Rome. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2008 , 8, 200-206		
7	Rheumatologie 2021. <i>Orthopädie Und Unfallchirurgie Up2date</i> , 2021 , 16, 607-625	0.1	
6	Regulatory T cells have anti-inflammatory effects by diluting TNF. <i>Future Rheumatology</i> , 2008 , 3, 231-234		
5	Januskinaseinhibitoren. <i>Journal Für Mineralstoffwechsel & Muskuloskelettale Erkrankungen</i> , 2017 , 24, 76-80	0.1	

4 Effector Mechanisms in Autoimmunity **2020**, 319-329

3 Treat-to-Target bei systemischem Lupus erythematosus. *Karger Kompass Autoimmun*, **2020**, 2, 45-51 ○

2 Response to: Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus by Wang. *Annals of the Rheumatic Diseases*, **2021**, 80, e193 2.4

1 Response to: New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS by Assan. *Annals of the Rheumatic Diseases*, **2019**, 2.4